The prosecution rests its case after submitting Government Exhibit 10 into evidence without objectio...It seems that these infusions from savings or gift cannot be interpreted as invested
1 duplicate copy in the archive
Regeneron/Sanofi press release on Praluent approval and pricing
Title Matchkaggle-ho-026365
Case Filed-17920House OversightRegeneron/Sanofi press release on Praluent approval and pricing
November 11, 20252p2 persons
Case File
d-17920House OversightRegeneron/Sanofi press release on Praluent approval and pricing
Other
The document is a standard pharmaceutical promotional release describing clinical trial results, pricing, and patient assistance programs. It contains no allegations, financial flows, or connections t Details of Phase 3 ODYSSEY trial efficacy and safety data for Praluent (alirocumab). Wholesale Acquisition Cost (WAC) disclosed at $40 per day. Patient assistance and co‑pay support programs outlined
Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #026365
Pages
2
Persons
2
Integrity
No Hash Available
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.